Attovia Therapeutics (ATTO) Stock Overview

A clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. More details

ATTO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue grew by 305.6% over the past year

Risk Analysis

Shares are highly illiquid

Less than 3 years of financial data is available

Does not have meaningful revenue ($1M)

ATTO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW471,153 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

471,153 investors already sharing narratives

View all narratives

Attovia Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Attovia Therapeutics
Historical stock prices
Current Share Price	US$19.18
52 Week High	US$22.79
52 Week Low	US$16.15
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-12.42%

Recent updates

Shareholder Returns

	ATTO	US Biotechs	US Market
7D	-5.9%	2.5%	1.7%
1Y	n/a	37.4%	20.0%

Return vs Industry: Insufficient data to determine how ATTO performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ATTO performed against the US Market.

Price Volatility

Is ATTO's price volatile compared to industry and market?
ATTO volatility
ATTO Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.1%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ATTO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ATTO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2022	44	Tao Fu	www.attovia.com

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn’s disease (CD).

Attovia Therapeutics, Inc. Fundamentals Summary

How do Attovia Therapeutics's earnings and revenue compare to its market cap?
ATTO fundamental statistics
Market cap	US$777.10m
Earnings (TTM)	-US$64.13m
Revenue (TTM)	US$1.35m

611.3x

P/S Ratio

-12.9x

P/E Ratio

Is ATTO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATTO income statement (TTM)
Revenue	US$1.35m
Cost of Revenue	US$58.96m
Gross Profit	-US$57.61m
Other Expenses	US$6.52m
Earnings	-US$64.13m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.49
Gross Margin	-4,267.26%
Net Profit Margin	-4,750.52%
Debt/Equity Ratio	0%

How did ATTO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/13 06:29
End of Day Share Price	2026/08/13 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Attovia Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Attovia Therapeutics, Inc.NasdaqGM:ATTO Stock Report